CN101633694A - 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 - Google Patents
抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 Download PDFInfo
- Publication number
- CN101633694A CN101633694A CN200810071473A CN200810071473A CN101633694A CN 101633694 A CN101633694 A CN 101633694A CN 200810071473 A CN200810071473 A CN 200810071473A CN 200810071473 A CN200810071473 A CN 200810071473A CN 101633694 A CN101633694 A CN 101633694A
- Authority
- CN
- China
- Prior art keywords
- ngf
- nerve growth
- growth factor
- antibody
- polyclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 150
- 102000015336 Nerve Growth Factor Human genes 0.000 title claims abstract description 145
- 229940053128 nerve growth factor Drugs 0.000 title claims abstract description 145
- 238000000034 method Methods 0.000 title claims abstract description 20
- 210000001913 submandibular gland Anatomy 0.000 claims abstract description 13
- 238000002965 ELISA Methods 0.000 claims abstract description 11
- 102000007072 Nerve Growth Factors Human genes 0.000 claims abstract description 5
- 230000002163 immunogen Effects 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- 238000007789 sealing Methods 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 238000003452 antibody preparation method Methods 0.000 claims description 8
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000003992 Peroxidases Human genes 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 238000004945 emulsification Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 239000012149 elution buffer Substances 0.000 claims description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000012148 binding buffer Substances 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 108090001008 Avidin Proteins 0.000 claims description 2
- 108050001427 Avidin/streptavidin Proteins 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000011091 antibody purification Methods 0.000 claims 1
- 238000010241 blood sampling Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 239000006228 supernatant Substances 0.000 abstract description 7
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 101710129634 Beta-nerve growth factor Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 102000046917 human NGF Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810071473A CN101633694B (zh) | 2008-07-24 | 2008-07-24 | 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810071473A CN101633694B (zh) | 2008-07-24 | 2008-07-24 | 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101633694A true CN101633694A (zh) | 2010-01-27 |
CN101633694B CN101633694B (zh) | 2012-08-29 |
Family
ID=41593045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810071473A Active CN101633694B (zh) | 2008-07-24 | 2008-07-24 | 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101633694B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613394B (zh) * | 2008-06-27 | 2012-07-18 | 厦门北大之路生物工程有限公司 | 鼠神经生长因子的制备方法和注射用鼠神经生长因子的制备方法 |
CN102766202A (zh) * | 2011-05-06 | 2012-11-07 | 中国科学院上海生命科学研究院 | Phf14 c端蛋白、其多克隆抗体及应用 |
CN103619879A (zh) * | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
CN106939041A (zh) * | 2017-04-14 | 2017-07-11 | 奔驰生物科技(云南)有限公司 | 应用多克隆抗体亲和柱纯化眼镜蛇毒神经生长因子的方法 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
CN109781977A (zh) * | 2019-01-09 | 2019-05-21 | 首都医科大学附属北京安定医院 | IL15Rα以及相关膜蛋白检测试剂盒及其应用 |
US10457727B2 (en) | 2010-12-01 | 2019-10-29 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
WO2021238886A1 (en) * | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
-
2008
- 2008-07-24 CN CN200810071473A patent/CN101633694B/zh active Active
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613394B (zh) * | 2008-06-27 | 2012-07-18 | 厦门北大之路生物工程有限公司 | 鼠神经生长因子的制备方法和注射用鼠神经生长因子的制备方法 |
US9738713B2 (en) | 2010-12-01 | 2017-08-22 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US10344083B2 (en) | 2010-12-01 | 2019-07-09 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9718882B2 (en) | 2010-12-01 | 2017-08-01 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75 |
US10457727B2 (en) | 2010-12-01 | 2019-10-29 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
CN103619879A (zh) * | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US10227402B2 (en) | 2010-12-01 | 2019-03-12 | Alderbio Holdings Llc | Anti-NGF antibodies and anti-NGF antibody fragments |
CN102766202B (zh) * | 2011-05-06 | 2014-08-27 | 中国科学院上海生命科学研究院 | Phf14 c端蛋白、其多克隆抗体及应用 |
CN102766202A (zh) * | 2011-05-06 | 2012-11-07 | 中国科学院上海生命科学研究院 | Phf14 c端蛋白、其多克隆抗体及应用 |
CN106939041B (zh) * | 2017-04-14 | 2020-10-16 | 奔驰生物科技(云南)有限公司 | 应用多克隆抗体亲和柱纯化眼镜蛇毒神经生长因子的方法 |
CN106939041A (zh) * | 2017-04-14 | 2017-07-11 | 奔驰生物科技(云南)有限公司 | 应用多克隆抗体亲和柱纯化眼镜蛇毒神经生长因子的方法 |
CN109781977A (zh) * | 2019-01-09 | 2019-05-21 | 首都医科大学附属北京安定医院 | IL15Rα以及相关膜蛋白检测试剂盒及其应用 |
WO2021238886A1 (en) * | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101633694B (zh) | 2012-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101633694B (zh) | 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 | |
US4857637A (en) | Methods and compositions for immunologically modulating growth hormone receptor activity | |
Moraga et al. | A τ fragment containing a repetitive sequence induces bundling of actin filaments | |
CA2201152A1 (en) | A monoclonal antibody to human ventricular myosin light chains | |
CN110272502A (zh) | 免疫原、分泌抗心肌肌钙蛋白i单克隆抗体的杂交瘤细胞及制备方法、单克隆抗体及应用 | |
Ryo et al. | Platelet factor 4 antigen in megakaryocytes | |
CN109596839A (zh) | 人和肽素快速定量检测方法与试剂盒 | |
CN108707586A (zh) | 抗内质网膜蛋白复合体亚单位10的单克隆抗体及其应用 | |
CN107290520A (zh) | 测定孕妇IgG抗‑A和抗‑B血型抗体或人血型反定型的免疫层析试纸条 | |
CN100476439C (zh) | 一种检测动物源性食品中氟喹酮类药物的酶联免疫试剂盒 | |
CN108103002B (zh) | Mdck细胞宿主残留蛋白的制备及其用途 | |
CN104066749B (zh) | 用于特异性识别人肝羧酸酯酶1的单克隆抗体、生成单克隆抗体的杂交瘤细胞株及其用途 | |
JPS6045599A (ja) | サイモシンβ4の免疫定量法 | |
CN110183530A (zh) | 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用 | |
CN100406116C (zh) | 净化沙丁胺醇和/或克伦特罗的方法及专用试剂盒 | |
Jackson et al. | The equilibrium constant for the interaction between a monoclonal Fab fragment and an influenza virus neuraminidase. | |
CN102183641A (zh) | 一种莱克多巴胺免疫层析检测试纸条 | |
EP0106615B1 (en) | Assay for the free portion of substances in biological fluids | |
CN116621978A (zh) | 一种用于β-CTX检测的抗体、试剂盒及其应用 | |
EP0401006B1 (en) | hANP antibody and method for immunological determination of hANP | |
CN101928332A (zh) | 一种人hnrpa0多肽及其抗体制备方法 | |
CN101928334B (zh) | 一种鼠Ehf多肽及其抗体制备方法 | |
CN105017414A (zh) | 偶联重组Pro-A和/或G多糖亲和介质及其应用 | |
CN108752480B (zh) | 一种免疫原组合物、其制备方法及其用途 | |
CN107266573B (zh) | 一种牛跨膜附睾蛋白1的多克隆抗体及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZOU YUFEI Owner name: BEIDAZHILU BIOLOGICAL ENGINEERING CO., LTD., XIAME Free format text: FORMER OWNER: REN HONGWEI Effective date: 20100722 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100722 Address after: Xiamen City, Fujian province 361009 Jinshang Road No. 80 North Park Applicant after: Xiamen Bioway Biotech Co., Ltd. Address before: Xiamen City, Fujian province 361009 Jinshang Road No. 80 North Park Applicant before: Ren Hongwei Co-applicant before: Zou Yufei |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: WEIMING BIOMEDICINE CO., LTD. Free format text: FORMER NAME: BEIDAZHILU BIOLOGICAL ENGINEERING CO., LTD., XIAMEN |
|
CP03 | Change of name, title or address |
Address after: Beijing University Biological Park Jinshang road 361009 of Fujian Province, Xiamen torch hi tech Zone No. 80 Patentee after: SINOBIOWAY BIOMEDICINE CO., LTD. Address before: Xiamen City, Fujian province 361009 Jinshang Road No. 80 North Park Patentee before: Xiamen Bioway Biotech Co., Ltd. |